#Singapore #Amai Proteins #sweelin® #food additive

Amai Proteins Achieves Regulatory Milestone in Singapore

Amai Proteins recently reached a significant regulatory achievement with the approval of its flagship product, sweelin®, by the Singapore Food Agency (SFA). This versatile sweet protein is now authorized for use as a sweetening agent in food and beverages, further solidifying Amai’s presence in the Asian market.

sweelin® represents a groundbreaking approach to sweeteners, presenting an avenue for substantial sugar reduction while maintaining flavor quality. Unlike traditional sweeteners, sweelin® provides a clean taste and complements existing formulations. The approval from the SFA follows the protein's earlier recognition by the FDA in the United States, where it was granted General Recognized as Safe (GRAS) status. This achievement not only expands Amai’s regulatory footprint but also emphasizes the global momentum in the acceptance of innovative food ingredients.

The unique composition of sweelin® as a sweet protein derived from precision fermentation makes it an environmentally sustainable option for manufacturers. It enables a competitive advantage in terms of cost and product labeling, allowing it to be branded as Serendipity Berry Sweet Protein in the U.S. market, aligning perfectly with growing consumer demands for clean-label and GLP-1-friendly ingredients.

Singapore has positioned itself as a leader in food technology innovation, embarking on initiatives like the “30 by 30” program, which aims to produce 30% of its nutritional needs locally by the year 2030. With its focus on developing sustainable food technologies, the SFA’s endorsement of sweelin® aligns seamlessly with the country's strategic objectives. This approval also marks the first instance of a sweet protein from precision fermentation being recognized in Singapore, thereby opening new pathways for commercialization and collaboration with local food and beverage manufacturers throughout the Asia-Pacific region.

Amai's journey with sweelin® has been marked by various significant milestones, including the completion of the first clinical trial involving a sweet protein, which successfully demonstrated that sweelin® does not influence blood glucose or insulin levels. These comprehensive studies reinforce the product's potential in the health-conscious market seeking alternative sweetening solutions.

“As we celebrate this important regulatory approval for sweelin® in Singapore, we acknowledge it as a critical milestone for Amai Proteins,” said Amir Guttman, CEO of Amai Proteins. “Singapore's regulatory framework showcases its global leadership in food innovation, and we are honored to have sweelin® as the first sweet protein from precision fermentation to gain approval here. This milestone not only confirms our regulatory strategies but also opens exciting commercial opportunities throughout Singapore and the broader Asia-Pacific region.”

In light of this recent approval, Amai Proteins is strategically engaging with potential partners and investors across the Asia-Pacific, gearing up for commercial rollout and scalability initiatives.

About Amai Proteins

Founded to develop, scale, and commercialize uniquely innovative sweet proteins, Amai Proteins operates at the intersection of food technology and sustainability. Its lead product, sweelin®, is derived from the serendipity berry and is approximately 3,000 times sweeter than sugar by weight. This protein is not only designed for cost-effectiveness but also to meet the demands of industrial food production processes, fitting well into a myriad of applications including beverages, candies, condiments, and dietary supplements. Through collaboration with leading food and supplement manufacturers, Amai ushers in possibilities for up to 70% sugar reduction, presenting a win-win for taste, cost-efficiency, and sustainability.

For further details, please reach out to Dr. Amir Guttman, CEO of Amai Proteins at [email protected]